BrainStorm Q2 net loss narrows to $2.5M; FDA alignment on NurOwn Phase 3b trial CMC

BRAINSTORM CELL THERAPEUTICS INC.

2024-Q2 EPS reported -$0.09

Net loss for Q2 2024 was $2.5M ($0.04/sh), compared to $5.3M ($0.13/sh) in Q2 2023.
Cash, cash equivalents, and restricted cash were $3.65M as of June 30, 2024.
Reached FDA alignment on CMC aspects for Phase 3b NurOwn trial in ALS, following SPA agreement in April.
Appointed Hartoun Hartounian Ph.D. as EVP/COO and promoted Dr. Bob Dagher to EVP/CMO.
Completed registered direct offering raising $4.0M gross proceeds from single institutional investor.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.